Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy

Starting soon · Phase 2

Conditions studied: Duchenne Muscular Dystrophy

In brief

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of KER-065 administered to adult and pediatric ambulatory and nonambulatory male participants with Duchenne Muscular Dystrophy (DMD) on stable background therapy.

Key facts

Study ID

NCT07704099

Run by

Keros Therapeutics, Inc.

People needed

36

Starts

2026-09-14

Expected to finish

2029-08-14

Last updated by the study team

2026-08-10

Who can join

Age: 9 and older. Sex: male. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.